Warning: DOMDocument::loadHTML(): ID docs-internal-guid-367178e3-7fff-30e7-70a5-6602badf3ea2 already defined in Entity, line: 2 in /home/dev/public_html/wp-content/themes/pru2.0/amp/single.php on line 52
Warning: DOMDocument::loadHTML(): ID docs-internal-guid-367178e3-7fff-30e7-70a5-6602badf3ea2 already defined in Entity, line: 3 in /home/dev/public_html/wp-content/themes/pru2.0/amp/single.php on line 52
Warning: DOMDocument::loadHTML(): ID docs-internal-guid-367178e3-7fff-30e7-70a5-6602badf3ea2 already defined in Entity, line: 4 in /home/dev/public_html/wp-content/themes/pru2.0/amp/single.php on line 52
Warning: DOMDocument::loadHTML(): htmlParseEntityRef: no name in Entity, line: 15 in /home/dev/public_html/wp-content/themes/pru2.0/amp/single.php on line 52
Warning: DOMDocument::loadHTML(): htmlParseEntityRef: no name in Entity, line: 15 in /home/dev/public_html/wp-content/themes/pru2.0/amp/single.php on line 52
Global Stem Cells Group, a multi-disciplinary community of scientists and physicians collaborating to
treat diseases and lessen human suffering through science, technology, and regenerative medicine, has announced their
participation in a clinical trial designed to explore the safety and improvement of treatment protocols using adipose-derived
stem cells.
The purpose of the investigation is to evaluate the safety of and superior effectiveness of adipose-derived stem cells in functional improvement in patients with partial-thickness rotator cuff tears (PTRCTs). The study will examine treatment results after the administration of a single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear compared to the administration of a single corticosteroid injection into the associated subacromial space.
Up to 20 centers in the United States have will be invited to enroll in the study. The trial seeks to target 246 subjects, with arandomized selection of which injection each subject will receive: the adipose-derived regenerative cell (ADRC) injection (ADRC treatment arm) or the SOC corticosteroid injection (active control arm). All subjects will be randomly assigned to the ADRC treatment or active control treatment at a 2:1 ratio.
The study is a double-blind trial in which the subject, post-procedural investigator and imaging core laboratorial radiologists are blinded. For more details on this clinical study, visit https://bit.ly/2Jw04aX.
Faculty members from the Global Stem Cells Group will be treating subjects enrolled in the study. Global was chosen to participate in this study due to its unique stature as a leader in regenerative medicine. The group is known for its comprehensive support of regenerative medicine solutions, starting with education, patient treatment and research and ending with the manufacturing and distribution of equipment for regenerative medicine practitioners.
To learn more about the Global Stem Cells Group, visit https://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
